September 24, 2024 01:00 AM EDT
R&D

Bio­gen, UCB de­clare Phase 3 lu­pus win and prep a sec­ond tri­al, but de­tails are scant

Max Gelman

Senior Editor

Bio­gen and UCB said Tues­day morn­ing that da­ta from a Phase 3 study for the lu­pus pro­gram dapirolizum­ab pe­gol were strong enough to con­vince it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Q&A: Bris­tol My­ers’ tech chief on the promis­es and per­ils of AI bio

As­traZeneca, Dai­ichi’s TROP2 drug miss­es over­all sur­vival goal in Phase 3 breast can­cer tri­al

Cor­rect­ed: Over a year af­ter FDA re­jec­tion, Bio­haven claims suc­cess in piv­otal neu­rode­gen­er­a­tive dis­ease study

UCB adds three more FDA ap­provals to la­bel for po­ten­tial block­buster Bimzelx

Is Sanofi mak­ing a move in­to obe­si­ty? French phar­ma in­vests $27M in­to Ven­tyx

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times